2014 first-quarter revenue
Growth on track for annual targets
Guerbet (GBT) reports 2014 first-quarter sales of €96.6 million, up 6.1% (+8.4% excluding currency effects) from the same period last year.
All product segments contributed to growth
For the quarter, sales in the MRI segment grew 5.1% to €38.9 million, bolstered in particular by a favourable price effect from Dotarem. Xenetix sales sustained gains in the X-ray segment that reached €28.9 million for the period (+7.4%). The Group will continue to invest in its new development platforms (for two new segments: Interventional Radiology and Medical Devices, and two fast-growing countries: USA, China).